Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 128
- Registration Number
- NCT04353375
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients
- Conditions
- Patient Safety
- Interventions
- Drug: Elunate®
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 3005
- Registration Number
- NCT04005066
- Locations
- 🇨🇳
Shanghai Dongfang Hospital, Shanghai, China
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 348
- Registration Number
- NCT03903705
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 53
- Registration Number
- NCT03786926
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio, Seville, Spain
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇪🇸Hospital Universitario Virgen Macarena, Seville, Spain
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 140
- Registration Number
- NCT03779113
- Locations
- 🇫🇮
Helsingin yliopistollinen keskussairaala, Helsinki, Finland
🇪🇸Institut Català d'Oncologia, Barcelona, Spain
🇵🇱Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego, Wrocław, Poland
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
- Conditions
- Triple Negative Breast CancerHER2-negative Breast CancerAdvanced Solid TumorsMetastatic Colon CancerMetastatic Breast CancerHormone Receptor Positive Breast CarcinomaRectal Cancer
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 129
- Registration Number
- NCT03251378
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 130
- Registration Number
- NCT02549937
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States